https://pipelinereview.com/ABLYNX-INITIATES-PHASE-I-BIOAVAILABILITY-STUDY-WITH-SUBCUTANEOUS-FORMULATION-OF-ITS-ANTI-IL-6R-NANOBODY-PARTNERED-WITH-ABBVIE/